The AngelPlus EIS Fund is an early-stage EIS technology fund (there is also a separate mirror SEIS fund). The Fund’s objective is to lead selective, early stage investments into UK based, technology and life science businesses using a unique “Venturer” approach which ensures all investments are nurtured actively: The fund only invests alongside Venturers who are experienced entrepreneurs and executives. These Venturers invest their own money and take an active board seat alongside Boundary Capital and its investment director in the investee company. This helps to promote success to de-risk them whilst adding value to the founders too. Further, there are no fees to pay by investors so 100% of their funds are invested.
Boundary Capital Partners LLP is a venture capital firm investing in early stage technology and life science companies. It was established in 2009 by successful technology entrepreneurs and investors.
The investment portfolios are co-managed by 5 Partners – Dan Somers, Dr Richard Leaver, Dr David Gee, Dr Adrian Parton and Grant Hawthorne. Ernie Richardson is strategic advisor working closely with the Partners. This experienced team have conceptualised, built, grown and realised technology businesses, as well as led over 14 Venture Capital funds with over £200m in management and achieved 60 exits. The fund multiples range from 1.4x to 3.0x.
In addition there are two Associate Partners – Damo Baliga and Stephen Barter alongside the 300+ Venturers who are signed up to support Boundary Capital’s unique ‘mammalian’ investment approach, i.e. to nurture their investments actively.
The key strategic considerations which underpin the Boundary Capital approach are:
The AngelPlus SEIS/ EIS Fund looks to spread each investors risk across at least 4 qualifying investment opportunities in the Boundary Capital investment portfolio based on their preference of SEIS or EIS investments. Each underlying SEIS/EIS company must have passed Boundary Capital’s due diligence process and have a best suited Venturer committed and aligned to execute a clear route to market.
» Boundary Capital have achieved their first exit at 4x return.
» Developments within portfolio include patent filing for AB-Polyblok, developing a revolutionary drug for curing and potentially reversing Alzheimer’s, Huntingdon’s and Parkinson’s
» Dymag, the carbon wheel manufacturer, launches new advanced series wheel at SEMA 2017
» Precision Sports Technologies launches its first product and makes first sales
If you are interested in further information about the Boundary Capital AngelPlus EIS& SEIS Fund
and future opportunities please contact us on firstname.lastname@example.org or +44 (0) 20 7952 6685.